The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1, open-label, first-in-human study of ABBV-969, a dual variable antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer.
 
Anthony Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Immunome; Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Affinia Therapeutics (Inst); Agenus (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bright Peak Therapeutics (Inst); Cullinan Oncology (Inst); Daiichi Sankyo, Inc. (Inst); Deka Biosciences (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Exelixis (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HiberCell (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); IMPAC Medical Systems (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Kirilys Therapeutics (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Link Immunotherapeutics (Inst); Medicxi (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mersana (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nerviano Medical Sciences (Inst); Nested Therapeutics (Inst); Novo Nordisk (Inst); Nurix (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Pierre Fabre (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); Qualigen Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); Singzyme Pte Ltd (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Sun Pharma Advanced Research Company (Inst); TheraTechnologies (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Venus Oncology (Inst); Verastem (Inst); Vincerx Pharma (Inst); VRise Therapeutics (Inst); Zentalis (Inst); ZielBio (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)
 
Tanya Dorff
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Novartis; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Hookipa Biotech (Inst); Janssen Oncology (Inst); Promontory Therapeutics (Inst)
 
Sumiko Okubo
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Linu Abraham
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Regina Reilly
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Claudina Stevenson
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Song Wang
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Ana Cole
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Sarah Mudd
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Samaneh Alaei
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Yuemei Wang
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
David Quinn
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Research Funding - Abbvie (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Point Therapeutics (Inst); Sanofi (Inst)
 
John Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc
Research Funding - Abbvie; Adagene (Inst); Alkermes; Allarity Therapeutics (Inst); Apros Therapeutics; Aptevo Therapeutics (Inst); Arcus Biosciences; Ascendis Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); Aulos Bioscience (Inst); BioBank Online (Inst); BioNTech SE (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; Cellgene Corp. (Inst); CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corbus Pharmaceuticals (Inst); Corvus Pharmaceuticals; CUE BioPharma (Inst); Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; GI Innovation (Inst); Glenmark Specialty SA (Inst); Harbour BioMed (Inst); I-Mab (Inst); IconOVir Bio (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; MBrace Therapeutics Inc. (Inst); Medikine (Inst); Merck (Inst); Modena TX (Inst); Molecular Templates (Inst); MT Group (Inst); Multitude Therapeutics Inc (Inst); NextCure (Inst); Nuvation Bio (Inst); PBD Biologics LTD (Inst); PEEL Therapeutics (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Qurgen (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Revolution Medicines Inc. (Inst); RiboScience (Inst); Sairopa (Inst); Seagen; Sequenom (Inst); Simcere (Inst); SK Life Sciences (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst)
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy